NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DC-24-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-052 from the NIH Guide for Grants and Contracts. There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.
Funding Opportunity RFA-DA-25-051 from the NIH Guide for Grants and Contracts. There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.
Notice NOT-GM-24-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-23-059 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support investigator-initiated research at all stages of development that is specifically focused on the development of medical countermeasures (MCMs) to mitigate/treat injuries arising from radiation exposure during a public health emergency. This funding opportunity will support the development of novel approaches within the radiation research area that may be considered for future licensure by the FDA.
Notice NOT-OD-24-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.
Notice NOT-CA-24-005 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-016 from the NIH Guide for Grants and Contracts
Notice NOT-DE-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-004 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-068 from the NIH Guide for Grants and Contracts
Notice to Close Funding Opportunity Announcement RFA-OH-22-001: NIOSH Education and Research Centers
Notice NOT-OH-24-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-046 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Community engaged research combined with rigorous qualitative research and diverse perspectives is needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children.
Notice NOT-AG-23-067 from the NIH Guide for Grants and Contracts
Notice NOT-RM-23-026 from the NIH Guide for Grants and Contracts
Notice NOT-DK-24-001 from the NIH Guide for Grants and Contracts
Notice NOT-NS-24-026 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-051 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm.
Funding Opportunity PAR-24-050 from the NIH Guide for Grants and Contracts. he NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.